Professor Kim Dong-hyun of the Department of Ophthalmology at Korea University Anam Hospital and the research team of RudaCure Inc. (CEO: Yongho Kim) have demonstrated the intraocular pressure-related safety of 'RCI001,' a novel treatment for inflammatory ocular diseases.
In a recent animal study, Professor Kim's research team administered a steroid formulation and RCI001 three times daily for five weeks, then compared intraocular pressure and ocular surface status. While five weeks of RCI001 administration did not cause any elevation in intraocular pressure or changes in the ocular surface, corticosteroid administration resulted in an approximately 38% increase in intraocular pressure compared to baseline.
Professor Kim stated, "Steroid formulations have historically been difficult to use long-term in clinical practice due to the risk of complications," adding, "This study has shown that RCI001 holds promise as an effective long-term anti-inflammatory agent for chronic ocular surface diseases requiring extended treatment, such as dry eye disease and Sjogren's syndrome, and I expect it to be of great benefit to patients in the future."
This research was published in the October 2023 issue of the international academic journal Frontiers under the title 'Comparison of RCI001 and corticosteroid on the effects on intraocular pressure in mice.'
Husaeng Ilbo: http://www.whosaeng.com/147434
Edaily: https://m.edaily.co.kr/news/read?newsId=02624006635774232&mediaCodeNo=257
Nate News: https://news.nate.com/view/20231018n12860?mid=n1101